Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 23, 2026 12:22 ET | Source: Research and Markets

U.S. AI-driven Diabetic Retinopathy Screening Market Trends 2026-2033 Featuring Profiles of Eyenuk, Digital Diagnostics, AEYE Health, Optomed, IRIS and Other Key Players

Dublin, March 23, 2026 (GLOBE NEWSWIRE) -- The "U.S. AI-driven Diabetic Retinopathy Screening Market Size, Share & Trends Analysis Report by Component, Screening, Deployment Mode, End Use, and...
March 23, 2026 07:02 ET | Source: Ocugen

Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy

MALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced...
March 18, 2026 08:07 ET | Source: Vanderbilt Report and Artelo Biosciences

Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical Study

Artelo Biosciences (NASDAQ: ARTL) enters ophthalmology space with a fully funded evaluating ART27.13 in glaucoma patients.
March 05, 2026 04:00 ET | Source: Oculis Holding AG

Oculis to Participate in Upcoming Investor Conferences

ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing...
March 04, 2026 08:15 ET | Source: Ocugen

Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results

Enrollment for the OCU400 Phase 3 liMeliGhT clinical trial—the first and largest gene therapy registrational trial for broad retinitis pigmentosa patients—was completed. Topline Phase 3 data expected...
March 03, 2026 07:02 ET | Source: EyeMD EMR Healthcare Systems, LLC

Optivate Is Here: A New Name, a Bolder Vision, and Continued Commitment to Elevating Ophthalmology

Optivate Is Here: A New Name, a Bolder Vision, and Continued Commitment to Elevating Ophthalmology
March 02, 2026 07:02 ET | Source: Ocugen

Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa

Enrollment for liMeliGhT, the first and largest gene therapy registrational trial for broad retinitis pigmentosa (RP) patients, was completed, reflecting strong interest from investigators and...
February 23, 2026 08:00 ET | Source: Precise Bio Inc.

Precise Bio Announces Successful Transplantation of Additional Patients in Ongoing Clinical Study of 3D-Bio-Printed Corneal Implant

Continued clinical progress follows regulatory authorization to advance study First patient continues to show dramatic vision restoration GREENSBORO, N.C., Feb. 23, 2026 (GLOBE NEWSWIRE) --...
February 18, 2026 17:13 ET | Source: Precise Bio Inc.

Precise Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

GREENSBORO, N.C., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Precise Bio, Inc. (“Precise Bio” or the “Company”), a clinical-stage regenerative medicine company pioneering bio-printed tissues and organs with...
February 18, 2026 10:35 ET | Source: Research and Markets

Glaucoma Drugs Competitive Landscape Report 2026: Comprehensive Insights About 100+ Companies and 110+ Drugs - Innovative Drug Developments Such As NCX 470 and QLS-111

Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "Glaucoma - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering. The report provides a thorough analysis of over 100...